Navigation Links
FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Date:9/23/2008

BROOMFIELD, Colo., Sept. 23 /PRNewswire/ -- ARCA biopharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for the company's lead product candidate, bucindolol, an investigational and pharmacologically unique beta-blocker and mild vasodilator developed for the treatment of chronic heart failure. If approved by the FDA, bucindolol could become the first genetically targeted cardiovascular therapy.

Bucindolol significantly reduces both hospitalizations and deaths in heart failure patients with a specific, common genetic variation compared to placebo, according to results from a prospectively defined genetic sub-study of the Beta Blocker Evaluation of Survival Trial (BEST), a large Phase III clinical trial funded and conducted by the National Institutes of Health and the Veterans Affairs Cooperative. This data was presented this week by Christopher O'Connor, M.D., director of the Heart Center at Duke University Medical Center, at the Heart Failure Society of America (HFSA) annual meeting in Toronto.

"Bucindolol has the potential to become an important new treatment for heart failure. Clinical responses to bucindolol are substantially enhanced when administered to genetically targeted heart failure populations," said Michael R. Bristow, M.D., chairman, chief science and medical officer, and founder of ARCA biopharma. "This makes it possible for physicians to personalize treatment with the goal of improving patient outcomes, reducing hospitalization and avoiding the 'trial and error' process that is common in treating heart failure patients today."

Dr. Bristow, along with Stephen Liggett, M.D. of the University of Maryland, conducted genetic research to identify heart failure patients who are most likely to respond to bucindolol therapy. This genetic subgroup constitutes approximately 50 percent of the U.S. heart failure population.

"By seeking regulatory approval for buci
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. FDA Accepts Immucors Response to Warning Letter
9. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... New York, NY (PRWEB) May 21, 2013 ... years. And according to My Cleaning Products, many turn to ... However, because of the health and environmental risks those solutions ... bugs with Bed Bug Bully instead. , According ... on bed bugs as they used to be. It shared ...
(Date:5/21/2013)... May 21, 2013 Inflamax scientists ... the ITN to design the study, which will ... key clinical models used in the study of ... Nasal Allergen Challenge (NAC) models. Although both the ... publications, to date no direct comparison between the ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... 23, 2010 Martek Biosciences, a company that launched ... University of Maryland, entered an agreement on December 21 ... NV for $1.1 billion, the companies jointly announced. ... is the second company sold for more than $1 ...
... Stanford University in the USA has an X-FEL (X-ray Free ... provides images of ,molecules in action, using a kilometer-long electron ... an alternative that can do many of the same things. ... half a million euro. That,s why the researchers have jokingly ...
... Md., Dec. 22, 2010 Novavax, Inc. (Nasdaq: ... Massachusetts Medical School, led by Dr. Trudy Morrison, published ... Virology, a report indicating that a novel virus-like particle ... mice from a live virus challenge.  This vaccine candidate ...
Cached Biology Technology:Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 2Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 3Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 4Eindhoven University builds affordable alternative to mega-laser X-FEL 2Eindhoven University builds affordable alternative to mega-laser X-FEL 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 4
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
(Date:5/18/2013)... 2013) Research presented at Digestive Disease Week ... through diet and lifestyle. , Individuals suffering ... muscle strength, fatigue and poor quality of life. ... in remission. A randomized, double blind, placebo-controlled study ... supplementation corresponded to significant relief of these symptoms. ...
(Date:5/17/2013)... provide the white noise of the South, but the night ... Southern air hangs heavy from the humidity and the sounds ... 140 species of frogs, toads and salamanders, is the center ... and swamps are the auditorium for their symphonic choruses, the ... Initiative, or ARMI, have front-row seats. , Amphibians, ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... clinical practice guideline, "Tonsillectomy in Children" will be published ... Surgery (watch for a new cover and publisher ... provides evidence-based recommendations on the pre-, intra-, and postoperative ... years under consideration for tonsillectomy. Additionally, this guideline is ...
... CORVALLIS, Ore. Members of the engineering faculty ... of radiation detection and measurement device that will be ... making the process faster, more accurate and less expensive. ... type of radiation spectrometer, and the first production of ...
... result in long waiting times for seriously ill patients. ... for the next available treatment. In this edition of ... 2010; 107[50]: 892𔃆), Michael Christ and his coauthors ... of emergency patients. Triage provides reliable methods that ...
Cached Biology News:Tonsillectomy in children 2New technology to speed cleanup of nuclear contaminated sites 2